Lower costs may improve access, expand prescribing opportunities, and support earlier intervention for high-risk patients
While the companys growth is impressive, driven by staggering Harvoni and Sovaldi sales of $13.9 billion and $5.3 billion, respectively, maintaining this surge within a more crowded Hep C market may prove difficult
Semaglutide does not need to be shaken and doing so could damage its components
Mol Genet Metab 94(4):397402
Common experiences during treatment include: Gradual weight loss : Most people experience greater losses in the first 3-6 months, with rates varying by dose and individual factors Reduced appetite and portion sizes : Many patients report feeling fuller sooner and experiencing fewer food cravings Gastrointestinal side effects : Nausea, diarrhoea, constipation, and abdominal discomfort are common, particularly during dose escalation
Prescription is considered only after a physicians evaluation